159 related articles for article (PubMed ID: 32880159)
1. [New possibilities in the treatment of Stargardt disease].
Zhorzholadze NV; Sheremet NL; Tanas AS; Strelnikov VV
Vestn Oftalmol; 2020; 136(4. Vyp. 2):333-343. PubMed ID: 32880159
[TBL] [Abstract][Full Text] [Related]
2. Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for Stargardt macular degeneration.
Radu RA; Hu J; Yuan Q; Welch DL; Makshanoff J; Lloyd M; McMullen S; Travis GH; Bok D
J Biol Chem; 2011 May; 286(21):18593-601. PubMed ID: 21464132
[TBL] [Abstract][Full Text] [Related]
3. Expression of ABCA4 in the retinal pigment epithelium and its implications for Stargardt macular degeneration.
Lenis TL; Hu J; Ng SY; Jiang Z; Sarfare S; Lloyd MB; Esposito NJ; Samuel W; Jaworski C; Bok D; Finnemann SC; Radeke MJ; Redmond TM; Travis GH; Radu RA
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11120-E11127. PubMed ID: 30397118
[TBL] [Abstract][Full Text] [Related]
4. Experimental studies on medical treatments of retinal dystrophies with a particular focus on ABCA4 retinopathies.
Sciezynska A; Ozieblo D; Oldak M
Klin Oczna; 2016 Aug; 118(1):59-65. PubMed ID: 29715411
[TBL] [Abstract][Full Text] [Related]
5. Stargardt macular dystrophy and evolving therapies.
Hussain RM; Ciulla TA; Berrocal AM; Gregori NZ; Flynn HW; Lam BL
Expert Opin Biol Ther; 2018 Oct; 18(10):1049-1059. PubMed ID: 30129371
[TBL] [Abstract][Full Text] [Related]
6. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease.
Lenis TL; Sarfare S; Jiang Z; Lloyd MB; Bok D; Radu RA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3987-3992. PubMed ID: 28348233
[TBL] [Abstract][Full Text] [Related]
7. Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation.
Radu RA; Yuan Q; Hu J; Peng JH; Lloyd M; Nusinowitz S; Bok D; Travis GH
Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3821-9. PubMed ID: 18515570
[TBL] [Abstract][Full Text] [Related]
8. Dual
Dyka FM; Molday LL; Chiodo VA; Molday RS; Hauswirth WW
Hum Gene Ther; 2019 Nov; 30(11):1361-1370. PubMed ID: 31418294
[TBL] [Abstract][Full Text] [Related]
9. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease.
Ma L; Kaufman Y; Zhang J; Washington I
J Biol Chem; 2011 Mar; 286(10):7966-7974. PubMed ID: 21156790
[TBL] [Abstract][Full Text] [Related]
10. Cell-Type-Specific Complement Profiling in the ABCA4
Jabri Y; Biber J; Diaz-Lezama N; Grosche A; Pauly D
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187113
[TBL] [Abstract][Full Text] [Related]
11. Gene Therapy of ABCA4-Associated Diseases.
Auricchio A; Trapani I; Allikmets R
Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017301. PubMed ID: 25573774
[TBL] [Abstract][Full Text] [Related]
12. Insights into the Molecular Properties of ABCA4 and Its Role in the Visual Cycle and Stargardt Disease.
Molday RS
Prog Mol Biol Transl Sci; 2015; 134():415-31. PubMed ID: 26310168
[TBL] [Abstract][Full Text] [Related]
13. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.
Charbel Issa P; Barnard AR; Herrmann P; Washington I; MacLaren RE
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8415-20. PubMed ID: 26106163
[TBL] [Abstract][Full Text] [Related]
14. Membrane Attack Complex Mediates Retinal Pigment Epithelium Cell Death in Stargardt Macular Degeneration.
Ng ESY; Kady N; Hu J; Dave A; Jiang Z; Pei J; Gorin MB; Matynia A; Radu RA
Cells; 2022 Nov; 11(21):. PubMed ID: 36359858
[TBL] [Abstract][Full Text] [Related]
15. An ABCA4 loss-of-function mutation causes a canine form of Stargardt disease.
Mäkeläinen S; Gòdia M; Hellsand M; Viluma A; Hahn D; Makdoumi K; Zeiss CJ; Mellersh C; Ricketts SL; Narfström K; Hallböök F; Ekesten B; Andersson G; Bergström TF
PLoS Genet; 2019 Mar; 15(3):e1007873. PubMed ID: 30889179
[TBL] [Abstract][Full Text] [Related]
16. Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes.
Hu J; Pauer GJ; Hagstrom SA; Bok D; DeBenedictis MJ; Bonilha VL; Hollyfield JG; Radu RA
Redox Biol; 2020 Oct; 37():101787. PubMed ID: 33214125
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutics for Stargardt disease.
Lu LJ; Liu J; Adelman RA
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1057-1062. PubMed ID: 28285324
[TBL] [Abstract][Full Text] [Related]
18. Stargardt-Fundus flavimaculatus: recent advancements and treatment.
Haji Abdollahi S; Hirose T
Semin Ophthalmol; 2013; 28(5-6):372-6. PubMed ID: 24138045
[TBL] [Abstract][Full Text] [Related]
19. A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle.
Racz B; Varadi A; Kong J; Allikmets R; Pearson PG; Johnson G; Cioffi CL; Petrukhin K
J Biol Chem; 2018 Jul; 293(29):11574-11588. PubMed ID: 29871924
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 Fatty Acids Supplementation: Therapeutic Potential in a Mouse Model of Stargardt Disease.
Prokopiou E; Kolovos P; Kalogerou M; Neokleous A; Nicolaou O; Sokratous K; Kyriacou K; Georgiou T
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):2757-2767. PubMed ID: 29860462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
